A 20-year-old man is newly diagnosed with HIV. During the past 14 months, he had intermittently been taking tenofovir DF-emtricitabine for HIV preexposure prophylaxis (PrEP). Initial laboratory studies show an HIV RNA level of 27,370 copies/mL. He is started on a regimen of dolutegravir plus tenofovir alafenamide-emtricitabine. He has never received cabotegravir for HIV PrEP. The baseline drug resistance genotype result returns 2 weeks later with only one mutation—the reverse transcriptase M184V mutation.